We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
126
CALL
Neurocrine Biosciences
NBIX
$17.7B
$1.44M 0.07%
365
-912
-71% -$36.2K
TTOO
127
DELISTED
T2 Biosystems, Inc
TTOO
$1.43M 0.07%
29
-17
-37% -$751K
VTRS icon
128
CALL
Viatris
VTRS
$20.1B
$1.41M 0.07%
304
-2,148
-88% -$104K
ENDP
129
DELISTED
Endo International plc
ENDP
$1.41M 0.07%
+50,000
New +$2.36M
AMRN
130
Amarin Corp
AMRN
$284M
$1.33M 0.07%
+43,540
New +$1.29M
AMRN
131
CALL
Amarin Corp
AMRN
$284M
$1.33M 0.07%
434
– –
XLRN
132
DELISTED
Acceleron Pharma
XLRN
$1.32M 0.07%
+50,000
New +$1.45M
BCLI
133
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.32M 0.07%
32,879
-18,423
-36% -$677K
FWP
134
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.3M 0.07%
10,969
+969
+10% +$109K
ACAD icon
135
Acadia Pharmaceuticals
ACAD
$4.25B
$1.29M 0.06%
46,258
-67,580
-59% -$1.47M
IMUC
136
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$1.28M 0.06%
110,284
-814
-0.7% -$9.16K
AKRX
137
DELISTED
Akorn Inc
AKRX
$1.26M 0.06%
+53,729
New +$1.41M
NUROW
138
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
$1.25M 0.06%
39,131
+158
+0.4% +$5.01K
MRTX
139
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.21M 0.06%
56,400
+30,373
+117% +$679K
CEMP
140
PUT
DELISTED
Cempra, Inc.
CEMP
$1.18M 0.06%
672
+257
+62% +$4.66K
OCRX
141
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.17M 0.06%
399,035
+13,735
+4% +$39.2K
MDGN.WS
142
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$1.17M 0.06%
1,564,370
+34,844
+2% +$10.6K
DVAX
143
PUT
DELISTED
Dynavax Technologies
DVAX
$1.16M 0.06%
605
+36
+6% +$728
OPK icon
144
Opko Health
OPK
$921M
$1.16M 0.06%
112,011
+14,200
+15% +$130K
RIBT
145
DELISTED
RiceBran Technologies
RIBT
$1.14M 0.06%
101,746
+8,402
+9% +$130K
OPK icon
146
PUT
Opko Health
OPK
$921M
$1.14M 0.06%
1,095
+142
+15% +$1.3K
LAB icon
147
Standard BioTools
LAB
$326M
$1.13M 0.06%
139,506
-124,690
-47% -$899K
SGYP
148
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.08M 0.05%
+392,273
New +$1.42M
CSBR icon
149
Champions Oncology
CSBR
$85.1M
$1.07M 0.05%
295,328
+3,733
+1% +$13.8K
XTLB
150
XTL Biopharmaceuticals
XTLB
$7.22M
$1.07M 0.05%
52,010
-3,588
-6% -$92.1K
4 5
6
7 8

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.